<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366610">
  <stage>Registered</stage>
  <submitdate>27/06/2014</submitdate>
  <approvaldate>10/07/2014</approvaldate>
  <actrnumber>ACTRN12614000731695</actrnumber>
  <trial_identification>
    <studytitle>A Phase I Study to Evaluate the Safety and Efficacy of Mesenchymal Stromal Cells (MSC) for Treating Chronic Obstructive Pulmonary Disease (COPD)</studytitle>
    <scientifictitle>A Phase I Study to Evaluate the Safety and Efficacy of Mesenchymal Stromal Cells (MSC) for Treating Chronic Obstructive Pulmonary Disease (COPD)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>COPD</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a safety study looking at the role of mesenchymal stem cells (MSCs) in the treatment of Chronic Pulmonary Pulmonary Disease (COPD). We will give COPD patients 2 infusions of MSCs. The first infusion will have labelled MSCs with Indium. Following the infusion, MSCs will be tracked using nuclear medicine imaging for 5 days. Thereafter, there will be a second infusion of unlabelled MSCs. Patients will be then followed up at clinics with particular assessment of symptoms, quality of life, lung function and imrpoved well being. 
The dose of MSC infusion (2 x 10 million/kg) per each of the two doses over 2 hours.
The second dose will be at day 7.
The MSCS are labelled with indium a radio-label. Therefore the stem cells will be tracked by scanning the patient and identifying the location of the stem cells on scans.
There is no controls to the study.</interventions>
    <comparator>No control. Treatment arm only.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Spirometry. Improvement in forced expratory volume in one second (FEV1) at 3, 6 months and 1 year by &gt;50ml.
Improvement in 6 Minute walk test by &gt;50m
The incidence of adverse events</outcome>
      <timepoint>3 months
6 months
1 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>There may be an allergic reaction to the stem cells. We will monitor the patients pulse, BP and oxygen levels. An increase in heart rate to &gt;120, drop in BP &lt;80 mmHg and a fall in oxygen to &lt;90%. we will stop the infusion and give the patient antihistamines and adrenaline if required. </outcome>
      <timepoint>day 1 and week 1</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement in COPD ASSESSMENT TOOL (CAT) by &gt;4.</outcome>
      <timepoint>3 months
6 months and 1 year.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>COPD
Moderate to severe COPD (GOLD 2-3)</inclusivecriteria>
    <inclusiveminage>60</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Inability to give consent
Cardiac failure
Renal failure
Liver failure
Active cancer

</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Patient suitability is deteremined by Dr Yuben Moodley - Principal Investigator. The patients who fulfill the inclusion and exclsuion criteria will then be given patient information and the offer to participate in the study. If they agree, consent is signed and the patient recruited. </concealment>
    <sequence>not applicable</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods> This is a safety trial and there was no specific statistical methods used.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/07/2014</anticipatedstartdate>
    <actualstartdate>24/06/2014</actualstartdate>
    <anticipatedenddate>24/12/2014</anticipatedenddate>
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Perth Hospital</primarysponsorname>
    <primarysponsoraddress>50 Murray Street
Perth
6000
Western Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Perth Hospital</fundingname>
      <fundingaddress>50 Murray Street
Perth
6000
Western Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Hypothesis: MSCs are safe in COPD.
Aims of trial ; To track MSCs post-infusion in the lung
To ensure safety of MSCs
We will infuse labelled MSCs and track them with nuclear imaging.
We will then do a second infusion of MSCs to monitor safety</summary>
    <trialwebsite>Nil</trialwebsite>
    <publication>Nil</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>Nil</publicnotes>
    <ethicscommitee>
      <ethicname>Royal Perth Human Ethics committee</ethicname>
      <ethicaddress>Colonial House
Murray Street
Perth
6000
Western Australia</ethicaddress>
      <ethicapprovaldate>19/02/2013</ethicapprovaldate>
      <hrec>2012/103</hrec>
      <ethicsubmitdate>25/10/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/366610-2012-103 Yuben Moodley FINAL.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/366610-Protocol EC2012-103 COPD Moodley V1 13 01 2012.doc</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Yuben Moodley</name>
      <address>School of Medicine and Pharmacology
University of Western Australia
50 Murray Street
Perth
6000
Western Australia</address>
      <phone>+61 8 92240232</phone>
      <fax>+61 8 92240246</fax>
      <email>yuben.moodley@uwa.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Yuben Moodley</name>
      <address>School of Medicine and Pharmacology
University of Western Australia
50 Murray Street
Perth
6000
Western Australia</address>
      <phone>+61 8 92240232</phone>
      <fax>+61 8 92240246</fax>
      <email>yuben.moodley@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Yuben Moodley</name>
      <address>School of Medicine and Pharmacology
University of Western Australia
50 Murray Street
Perth
6000
Western Australia</address>
      <phone>+61 8 92240232</phone>
      <fax>+61 8 92240246</fax>
      <email>yuben.moodley@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Yuben Moodley</name>
      <address>50 Murray Street
Perth
6000
Western Australia</address>
      <phone>+61 8 92240232</phone>
      <fax>+61 8 92240246</fax>
      <email>yuben.moodley@uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>